ArticleCurrent oncology (Toronto, Ont.)2020
Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada.
Article in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.Journal for immunotherapy of cancer · 2026Trial
- Article
- Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.Current oncology (Toronto, Ont.) · 2026Article
- Development and validation of a dynamic nomogram for predicting brain metastasis in stage III NSCLC patients undergoing definitive chemoradiotherapy.BMC cancer · 2025Article
- NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata.JTO clinical and research reports · 2025Article
- Amivantamab as a salvage therapy post-EGFR-tyrosine kinase inhibitor failure in patients with mutated EGFR non-small cell lung cancer.Translational lung cancer research · 2025Article
- Quality Indicators for Non-Small Cell Lung Cancer in Queensland, Australia, 2012-2021.Thoracic cancer · 2025Article
- JAK2 Loss Arising From Tumor-Spread-Through-Air-Spaces (STAS) Promotes Tumor Progression by Suppressing CD8+ T Cells in Lung Adenocarcinoma: A Machine Learning Approach.Journal of Korean medical science · 2024Article
- Real-World Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Early-Stage Non-Small-Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2024Article
- Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic.Frontiers in oncology · 2023Article
- Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.Cancer treatment and research communications · 2023Article
- Real-world treatment pattern and prognostic factors of stage IV lung squamous cell carcinoma patients.The Kaohsiung journal of medical sciences · 2022Article
- Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world.Cancer medicine · 2022Article
- Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.Current oncology (Toronto, Ont.) · 2021Observational
- Article
- Target Aggregate Data Adjustment Method for Transportability Analysis Utilizing Summary-Level Data From the Target Population.Pharmaceutical statisticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Almost half of all patients with non-small-cell lung cancer (nsclc) present with stage iv disease. The objective of the present study was to characterize treatment patterns and survival outcomes in patients with advanced nsclc. Methods: We conducted a longitudinal population-level study in patients diagnosed with stage iv nsclc in Ontario between 1 April 2010 and 31 March 2015, with follow-up to 31 March 2017 for overall survival and treatment sequence. Patients were stratified as nonsquamous or squamous histology. A sub-analysis was conducted for patients with nonsquamous histology who received targeted therapies, on the assumption that their tumours were Results: Of 24,729 nsclc cases identified, stage iv disease was diagnosed in 49.2%, histology was nonsquamous in 10,103, and Conclusions: Survival of patients with stage iv nsclc remains poor, with the exception of patients who are
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.